This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shanafelt, T. D. Articles by Dewald, G. W. Search for Related Content PubMed PubMed Citation Articles by Shanafelt, T. D. Articles by Dewald, G. W. Social Bookmarking                            What's this?

Prospective Evaluation of Clonal Evolution During Long-Term Follow-Up of Patients With Untreated Early-Stage Chronic Lymphocytic Leukemia

Tait D. Shanafelt, Thomas E. Witzig, Stephanie R. Fink, Robert B. Jenkins, Sarah F. Paternoster, Stephanie A. Smoley, Kimberly J. Stockero, Danielle M. Nast, Heather C. Flynn, Renee C. Tschumper, Susan Geyer, Clive S. Zent, Tim G. Call, Diane F. Jelinek, Neil E. Kay, Gordon W. Dewald

From the Mayo Clinic College of Medicine, Department of Internal Medicine, Division of Hematology, Department Pathology, Division of Cytogenetics, Department of Immunology, Division of Biostatistics, Mayo Clinic, Rochester, MN

Address reprint requests to Tait D. Shanafelt, MD, 200 First Street SW, Mayo Clinic, Rochester, MN 55905

PURPOSE: Retrospective studies suggest cytogenetic abnormalities detected by interphase fluorescent in situ hybridization (FISH) can identify patients with chronic lymphocytic leukemia (CLL) who will experience a more aggressive disease course. Other studies suggest that patients may acquire chromosome abnormalities during the course of their disease. There are minimal prospective data on the clinical utility of the widely used hierarchical FISH prognostic categories in patients with newly diagnosed early-stage CLL or the frequency of clonal evolution as determined by interphase FISH.

PATIENTS AND METHODS: Between 1994 and 2002, we enrolled 159 patients with previously untreated CLL (83% Rai stage 0/I) on a prospective trial evaluating clonal evolution by FISH. Patients provided baseline and follow-up specimens for FISH testing during 2 to 12 years.

RESULTS: Chromosomal abnormalities detected by FISH at study entry predicted overall survival. Eighteen patients experienced clonal evolution during follow-up. The rate of clonal evolution increased with duration of follow-up with only one occurrence in the first 2 years (n = 71; 1.4%) but 17 occurrences (n = 63; 27%) among patients tested after 5+ years. Clonal evolution occurred among 10% of ZAP-70–negative and 42% of ZAP-70–positive patients at 5+ years (P = .008).

CONCLUSION: This clinical trial confirms prospectively that cytogenetic abnormalities detected by FISH can predict overall survival for CLL patients at the time of diagnosis, but also suggests that many patients acquire new abnormalities during the course of their disease. Patients with higher ZAP-70 expression may be more likely to experience such clonal evolution. These findings have important implications for both clinical management and trials of early treatment for patients with high-risk, early-stage CLL.

Supported by grants from Vysis Inc, Des Plaines, IL (G.D., R.J., T.W.), and Grants No. NCI K12 CA90628 and NCI Lymphoma SPORE CA97274 (S.F.).

Presented at the 47th Annual Meeting of the American Society of Hematology, Atlanta, GA, December 10-13, 2005.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				T. D. Shanafelt, N. E. Kay, K. G. Rabe, T. G. Call, C. S. Zent, K. Maddocks, G. Jenkins, D. F. Jelinek, W. G. Morice, J. Boysen, et al. Brief Report: Natural History of Individuals With Clinically Recognized Monoclonal B-Cell Lymphocytosis Compared With Patients With Rai 0 Chronic Lymphocytic Leukemia J. Clin. Oncol., August 20, 2009; 27(24): 3959 - 3963. [Abstract] [Full Text] [PDF]

				C. S. Tam, T. D. Shanafelt, W. G. Wierda, L. V. Abruzzo, D. L. Van Dyke, S. O'Brien, A. Ferrajoli, S. A. Lerner, A. Lynn, N. E. Kay, et al. De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience Blood, July 30, 2009; 114(5): 957 - 964. [Abstract] [Full Text] [PDF]

				T. D. Shanafelt, N. E. Kay, G. Jenkins, T. G. Call, C. S. Zent, D. F. Jelinek, W. G. Morice, J. Boysen, L. Zakko, S. Schwager, et al. B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome Blood, April 30, 2009; 113(18): 4188 - 4196. [Abstract] [Full Text] [PDF]

				G. S. Nowakowski, J. D. Hoyer, T. D. Shanafelt, C. S. Zent, T. G. Call, N. D. Bone, B. LaPlant, G. W. Dewald, R. C. Tschumper, D. F. Jelinek, et al. Percentage of Smudge Cells on Routine Blood Smear Predicts Survival in Chronic Lymphocytic Leukemia J. Clin. Oncol., April 10, 2009; 27(11): 1844 - 1849. [Abstract] [Full Text] [PDF]

				D. Rossi, M. Cerri, C. Deambrogi, E. Sozzi, S. Cresta, S. Rasi, L. De Paoli, V. Spina, V. Gattei, D. Capello, et al. The Prognostic Value of TP53 Mutations in Chronic Lymphocytic Leukemia Is Independent of Del17p13: Implications for Overall Survival and Chemorefractoriness Clin. Cancer Res., February 1, 2009; 15(3): 995 - 1004. [Abstract] [Full Text] [PDF]

				T. J. Kipps Chronic Lymphocytic Leukemia: Advances in Assessing Prognosis and Therapy ASCO Educational Book, January 1, 2009; 2009(1): 385 - 393. [Abstract] [Full Text] [PDF]

				L. Kujawski, P. Ouillette, H. Erba, C. Saddler, A. Jakubowiak, M. Kaminski, K. Shedden, and S. N. Malek Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia Blood, September 1, 2008; 112(5): 1993 - 2003. [Abstract] [Full Text] [PDF]

				M. Hallek, B. D. Cheson, D. Catovsky, F. Caligaris-Cappio, G. Dighiero, H. Dohner, P. Hillmen, M. J. Keating, E. Montserrat, K. R. Rai, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines Blood, June 15, 2008; 111(12): 5446 - 5456. [Abstract] [Full Text] [PDF]

				T. D. Shanafelt, C. Hanson, G. W. Dewald, T. E. Witzig, B. LaPlant, J. Abrahamzon, D. F. Jelinek, and N. E. Kay Karyotype Evolution on Fluorescent In Situ Hybridization Analysis Is Associated With Short Survival in Patients With Chronic Lymphocytic Leukemia and Is Related to CD49d Expression J. Clin. Oncol., May 10, 2008; 26(14): e5 - e6. [Full Text] [PDF]

				C. Saddler, P. Ouillette, L. Kujawski, S. Shangary, M. Talpaz, M. Kaminski, H. Erba, K. Shedden, S. Wang, and S. N. Malek Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia Blood, February 1, 2008; 111(3): 1584 - 1593. [Abstract] [Full Text] [PDF]

				T. J. Kipps Chronic Lymphocytic Leukemia: Prognostic Markers and Revised Criteria for Treatment and Response Assessment ASCO Educational Book, January 1, 2008; 2008(1): 286 - 290. [Abstract] [Full Text] [PDF]

				S. Stilgenbauer, S. Sander, L. Bullinger, A. Benner, E. Leupolt, D. Winkler, A. Krober, D. Kienle, P. Lichter, and H. Dohner Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival Haematologica, September 1, 2007; 92(9): 1242 - 1245. [Abstract] [Full Text] [PDF]

				T. D. Shanafelt and N. E. Kay Comprehensive Management of the CLL Patient: A Holistic Approach Hematology, January 1, 2007; 2007(1): 324 - 331. [Abstract] [Full Text] [PDF]

				Clonal Evolution in Chronic Lymphocytic Leukemia Journal Watch Oncology and Hematology, November 13, 2006; 2006(1113): 2 - 2. [Full Text]